Abrocitinib Attenuates Microglia-Mediated Neuroinflammation after Traumatic Brain Injury via Inhibiting the JAK1/STAT1/NF-κB Pathway

Background and Purpose: Neuroinflammation has been shown to play a critical role in secondary craniocerebral injury, leading to poor outcomes for TBI patients. Abrocitinib, a Janus kinase1 (JAK1) selective inhibitor approved to treat atopic dermatitis (AD) by the Food and Drug Administration (FDA),...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Tuo, Li, Lei, Peng, Ruilong, Hao, Hongying, Zhang, Hejun, Gao, Yalong, Wang, Cong, Li, Fanjian, Liu, Xilei, Chen, Fanglian, Zhang, Shu, Zhang, Jianning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688110/
https://www.ncbi.nlm.nih.gov/pubmed/36429017
http://dx.doi.org/10.3390/cells11223588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688110/
https://www.ncbi.nlm.nih.gov/pubmed/36429017
http://dx.doi.org/10.3390/cells11223588

Ejemplares similares